With commercial sales of Avenova™ accelerating, the stock of NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is certainly on the TKO radar.
NovaBay Pharmaceuticals, Inc. (“NovaBay” or NBY) is a commercial stage company which launched its eye care product, Avenova with Neutrox™, in August 2014. The product is targeting a substantial evergreen market of 30 million Americans suffering from the chronic eyelid inflammation disease known as Blepharitis. Symptoms include dry and itchy eyes, contact lens discomfort, and eye discharge. Blepharitis is a form of staph bacteria that can lead to complications including conjunctivitis, dry eye syndrome and cornea damage. Avenova with Neutrox™ is a proven effective daily cleanse treatment for Blepharitis when used daily.
NovaBay also started the commercial launch of its wound care product NeutroPhase® in China. NBY reported their Chinese partner placed an order for 200,000 units which are undergoing fulfillment. The commercial launch for NeutroPhase® also includes partners in the USA, Ukraine, Egypt, Saudi Arabia, South Korea and more. These distribution channels could be useful for NBY in the future as the company has many more products in their pipeline using their anti-infection solutions.
If all goes according to company projections, NBY stock should do nicely as sales continue to grow through 2015. NovaBay Pharmaceuticals, Inc. (NBY) stock is currently trading around $0.75 a share with a 52-week low of $0.42 and the high hitting $1.30 in August 2014.
Stay tuned TKO’ers!